Drugs / WP1302
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06240455 Comparator | Mar 2026 → Mar 2029 | Graves disease | Worg Biotherapeutics Inc. | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WP1302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06240455 ↗ |
| Route | Subcutaneous | “WP1302 or placebo by subcutaneous (S.C.) injection” NCT06240455 ↗ |